SAFETY AND EFFICACY FINDINGS OF A PHASE 1B/2 STUDY OF NANATINOSTAT PLUS VALGANCICLOVIR FOR TREATMENT OF RELAPSED/REFRACTORY EPSTEIN-BARR VIRUS-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
a Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil
b Division of Hematology, A Beneficência Portuguesa de São Paulo (BP), São Paulo, Brazil
c Division of Hematology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, Brazil
d Division of Hematology, University of Colorado, Denver, United States
e Applied Statistics and Consulting, Spruce Pine, United States
f Viracta Therapeutics, Inc., Cardiff, United States
g Division of Hematologic Malignancies and Hematopoetic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, United States
Read
877
Timeswas read the article
343
Total PDF
534
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 May | 15 | 6 | 21 |
| 2025 April | 44 | 14 | 58 |
| 2025 March | 51 | 8 | 59 |
| 2025 February | 33 | 11 | 44 |
| 2025 January | 24 | 24 | 48 |
| 2024 December | 19 | 12 | 31 |
| 2024 November | 25 | 14 | 39 |
| 2024 October | 34 | 18 | 52 |
| 2024 September | 42 | 23 | 65 |
| 2024 August | 34 | 20 | 54 |
| 2024 July | 38 | 25 | 63 |
| 2024 June | 32 | 23 | 55 |
| 2024 May | 37 | 21 | 58 |
| 2024 April | 36 | 9 | 45 |
| 2024 March | 22 | 20 | 42 |
| 2024 February | 14 | 23 | 37 |
| 2024 January | 14 | 21 | 35 |
| 2023 December | 12 | 23 | 35 |
| 2023 November | 6 | 16 | 22 |
| 2023 October | 2 | 12 | 14 |
Show all
